سعر يونيتركسات Unitrexate‏ 50مجم/2مل 5 فيال 2026

Methotrexate 50 mg solution for intramuscular/intravenous injection or intravenous infusion; 5 vials of 2 ml (25 mg/ml).

• Common: ulcerative stomatitis, leukopenia, nausea and abdominal distress; also infections, fatigue, chills, fever, dizziness.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of severe hypersensitivity to methotrexate; pregnancy in patients with non-neoplastic diseases.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious toxicities: embryo-fetal toxicity, hypersensitivity, myelosuppression, serious infections, renal, gastrointestinal, hepatic, pulmonary and dermatologic toxicity, secondary malignancies, tumor lysis syndrome; avoid live vaccines.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Medication errors with daily instead of weekly dosing have caused deaths.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs increasing methotrexate exposure (e.g. NSAIDs, probenecid, penicillins, proton pump inhibitors)May increase methotrexate concentrations and severe toxicity; monitor closely if co-administration cannot be avoided.DailyMed (U.S. National Library of Medicine)
• TheophyllineMethotrexate increases theophylline concentrations; monitor theophylline levels.DailyMed (U.S. National Library of Medicine)
• Folic acid / folinic acid productsIn neoplastic disease may reduce methotrexate effectiveness; in RA/pJIA/psoriasis folic or folinic acid is given to reduce toxicity.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnant women with non-neoplastic diseases; can cause embryo-fetal toxicity and fetal death. Use effective contraception during and after treatment as per label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Methotrexate: DHFR inhibitor blocking tetrahydrofolate-dependent DNA/RNA/protein synthesis.